A phase II study of dupilumab as an adjunctive therapy to immunotherapies for the treatment of grass allergy.
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2017
At a glance
- Drugs Dupilumab (Primary)
- Indications Grass pollen hypersensitivity
- Focus Therapeutic Use
- 19 Dec 2017 New trial record
- 13 Dec 2017 According to a Regeneron pharmaceutical media release, this study is planned to initiate in 2018.